HOME >> MEDICINE >> NEWS
Implantable defibrillators cost-effective for preventing sudden death

collected on a subgroup of 237 patients, who were a balanced representation of the larger trial, geographically and medically.

We called these the shoebox patients, because we told them we wanted all their bills just bring them in a shoebox, says Larsen. The researchers converted the charges to 1997 costs. Three-year survival data from AVID were used to calculate the base cost effectiveness (C/E ratio). Six-year, 20-year and lifetime C/E ratios were also estimated.

The researchers determined that the largest expense for these patients is inpatient care, which makes up between 73 percent of total costs for drug therapy patients and 84 percent for ICD patients. At three years, the cost for the drug treatment group was $71,421. For the defibrillator group it was $85,522. The ICD provided a 0.21-year average survival benefit, putting the cost-effectiveness ratio at $66,677 per year of life saved.

The defibrillator patients lived longer, but they paid extra to get that extra life. The ratio of the additional amount paid for the additional survival benefit is the cost-effectiveness number, Larsen says.

According to Larsen, the conventional wisdom about cost-effectiveness ratios is that something is a bargain below about $50,000 per year of life saved, so the defibrillator is just on the margin of that bargain. Its on the high side but not out of reason.

The researchers also found that six- and 20-year C/E ratios remained stable between $68,000 and $80,000 per year of life saved.

This is only the beginning when it comes to cost-effectiveness studies on the devices, Larsen says. The cost effectiveness issue is going to be a very big part of the defibrillator story during the next year or two as more and more people look to ICDs for treatment.

For example, there may be changes in some of the big expenses from the ICD group, such as how often the ICD battery may need to be replaced, he says. At three
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
15-Apr-2002


Page: 1 2 3

Related medicine news :

1. Implantable heart defibrillators
2. Statement: Implantable medical identification chip
3. Implantable cardiac defibrillator use significantly lowers heart failure mortality
4. Implantable device pumps up ailing heart
5. Implantable heart device reduces deaths by one-third
6. Implanted defibrillators cut heart patients death risk, some more than others
7. Implanted defibrillators not covered for half of patients who could benefit, study finds
8. More doubts over value of defibrillators
9. One use every seven years makes automated external defibrillators a good buy
10. Benefit of public defibrillators is marginal
11. Health and fitness facilities need defibrillators

Post Your Comments:
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... Boston, Massachusetts (PRWEB) May 22, 2015 ... conditions is a difficult process. Historically providers have ... efforts by payers. Starting in 2015, Medicare has ... care coordination activities. Thanks to the launch of ... technology, providers and health systems using the platform ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning of ... tips to help promote safe travel. , According to estimates ... fatalities this Memorial Day weekend. Amica is sharing the following ... , , Always wear a seatbelt: ... whether they’re driving or riding along as a passenger. Seatbelts ...
(Date:5/22/2015)... Seattle, WA (PRWEB) May 22, 2015 According ... adults of all generations are equally as likely to worry ... (72% Millennials, 75% Gen X, 77% Boomers, 69% Silent Generation), ... (45%) agree they are scared of aging, particularly Millennials (47%), ... online by Harris Poll in April, 2015 among more than ...
(Date:5/22/2015)... Power Systems is proud to announce the ... season. Drobeck is in his second year of racing in ... the Missoula Fire Department in Missoula, MT. He entered the ... During his career, he has had 15 1st Place finishes. ... 10 finishes in all seven of his 2014 races, including ...
Breaking Medicine News(10 mins):Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
(Date:5/22/2015)... May 22, 2015  The U.S. Food and ... -- the first biosimilar product approved in ... toward growth in the contract manufacturing organization (CMO) ... industry is geared to the production of small-molecular ... biopharmaceutical products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... YORK and KING OF PRUSSIA, Pa. ... Foundation (NHF) has awarded CSL Behring its ... and unwavering commitment to advancing science and improving the care ... Paul Perreault , CEO and Managing Director, CSL Limited, ... York City on May 21. "The ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Cached News: